- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Rezolute, Inc. initiated clinical trials in Europe and received a streamlined development path from the FDA.
1 report, 1 independent
Updated Sep 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Rezolute, Inc. initiated clinical trials in Europe and received a streamlined development path from the FDA.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- The FDA is reviewing the BLA submission from Ultragenyx Pharmaceutical, with Eric Crombez serving as chief medical officer.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- OKYO Pharma is conducting clinical trials in Europe and Italy while seeking FDA approval for its investigational therapy.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Arthur Caplan questioned the FDA regarding the status of clinical trials in 2006.
Coverage
Newest first; wire copies grouped- GlobeNewswireRezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism Open-label study in as few as 16 tumor hyperinsulinism (HI) patients Study